Daptomycin - Revision history

Danbot: Add AntibioticDose SMW query table for dynamic indications by disease

2026-03-20T20:38:10Z

Add AntibioticDose SMW query table for dynamic indications by disease

@@ Line 16: / Line 16: @@
 **HD: give dose after dialysis, no supplement
 **PD: no supplement
 ==Pediatric Dosing==
 *Unavailable
 ==Special Populations==

Elcatracho: /* Serious */

2022-01-03T09:16:08Z

Serious

← Older revision		Revision as of 09:16, 3 January 2022
Line 42:		Line 42:
	*Superinfection		*Superinfection
	*Eosinophilic pneumonia		*Eosinophilic pneumonia
	*Anaphylaxis		*[[Anaphylaxis]]
	*Drug rash		*Drug rash
	*Thrombocytopenia		*[[Thrombocytopenia]]
	*Myopathy		*Myopathy
	*Rhabdomyolysis		*[[Rhabdomyolysis]]
	*Peripheral neuropathy		*Peripheral neuropathy

ClaireLewis at 23:52, 20 September 2019

2019-09-20T23:52:16Z

← Older revision		Revision as of 23:52, 20 September 2019
Line 1:		Line 1:
	==General==		==General==
	*Type: bacterial antibiotic		*Type: bacterial [[antibiotic]]
	*Dosage Forms: IV		*Dosage Forms: IV
	*Common Trade Names: Cubicin		*Common Trade Names: Cubicin
Line 192:		Line 192:
	<references/>		<references/>
	[[Category:Pharmacology]]		[[Category:Pharmacology]]
			[[Category:ID]]

Rossdonaldson1: Text replacement - "vancomycin " to "vancomycin "

2019-07-04T03:39:56Z

Text replacement - "vancomycin " to "vancomycin "

← Older revision		Revision as of 03:39, 4 July 2019
Line 5:		Line 5:
	*Good soft tissue and MSK penetration, but poor lung penetration as it is inactivated by pulmonary surfactant<ref>Estes KS and Derendorf K. Comparison of the pharmacokinetic properties of vancomycin, linezolid, tigecyclin, and daptomycin. Eur J Med Res. 2010; 15(12): 533–543.</ref><ref>Silverman JA et al. Inhibition of Daptomycin by Pulmonary Surfactant: In Vitro Modeling and Clinical Impact. J Infect Dis. (2005) 191 (12): 2149-2152.</ref>		*Good soft tissue and MSK penetration, but poor lung penetration as it is inactivated by pulmonary surfactant<ref>Estes KS and Derendorf K. Comparison of the pharmacokinetic properties of vancomycin, linezolid, tigecyclin, and daptomycin. Eur J Med Res. 2010; 15(12): 533–543.</ref><ref>Silverman JA et al. Inhibition of Daptomycin by Pulmonary Surfactant: In Vitro Modeling and Clinical Impact. J Infect Dis. (2005) 191 (12): 2149-2152.</ref>
	**Daptomycin is typically added to treat community enterococcus or [[vancomycin-resistant enterococcus]], but VRE pneumonia requires [[linezolid]]		**Daptomycin is typically added to treat community enterococcus or [[vancomycin-resistant enterococcus]], but VRE pneumonia requires [[linezolid]]
	**Add MRSA antibiotic with adequate lung penetration such as [[linezolid]] at standard dosing or [[vancomycin]] dosing aimed at higher serum concentrations<ref>Stein GE and Wells EM. The importance of tissue penetration in achieving successful antimicrobial treatment of nosocomial pneumonia and complicated skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus: vancomycin and linezolid. Curr Med Res Opin. 2010 Mar;26(3):571-88.</ref>		**Add MRSA antibiotic with adequate lung penetration such as [[linezolid]] at standard dosing or [[vancomycin]] dosing aimed at higher serum concentrations<ref>Stein GE and Wells EM. The importance of tissue penetration in achieving successful antimicrobial treatment of nosocomial pneumonia and complicated skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus: [[vancomycin]] and linezolid. Curr Med Res Opin. 2010 Mar;26(3):571-88.</ref>

	==Adult Dosing==		==Adult Dosing==

Mholtz: Text replacement - "==References== " to "==References== "

2017-10-26T02:39:22Z

Text replacement - "==References== <references/>" to "==References== <references/>"

← Older revision		Revision as of 02:39, 26 October 2017
Line 190:		Line 190:

	==References==		==References==

	<references/>		<references/>
	[[Category:Pharmacology]]		[[Category:Pharmacology]]

Mholtz: Text replacement - "==Source==" to "==References=="

2017-08-31T06:09:00Z

Text replacement - "==Source==" to "==References=="

← Older revision		Revision as of 06:09, 31 August 2017
Line 189:		Line 189:
	==See Also==		==See Also==

	==~~Source~~==		==References==

	<references/>		<references/>
	[[Category:Pharmacology]]		[[Category:Pharmacology]]

Rossdonaldson1: Text replacement - "Chest pain" to "Chest pain"

2016-09-25T20:41:03Z

Text replacement - "*Chest pain" to "*Chest pain"

← Older revision		Revision as of 20:41, 25 September 2016
Line 53:		Line 53:
	*Pharyngeal pain		*Pharyngeal pain
	*Elevated CK		*Elevated CK
	*Chest pain		*[[Chest pain]]
	*Edema		*Edema
	*Abdominal pain		*Abdominal pain

Rossdonaldson1: Text replacement - "Diarrhea" to "Diarrhea"

2016-09-24T12:20:22Z

Text replacement - "*Diarrhea" to "*Diarrhea"

← Older revision		Revision as of 12:20, 24 September 2016
Line 58:		Line 58:
	*Pruritis		*Pruritis
	*Headache		*Headache
	*Diarrhea		*[[Diarrhea]]

	==Pharmacology==		==Pharmacology==

Kxl328 at 22:08, 26 August 2016

2016-08-26T22:08:40Z

← Older revision		Revision as of 22:08, 26 August 2016
Line 4:		Line 4:
	*Common Trade Names: Cubicin		*Common Trade Names: Cubicin
	*Good soft tissue and MSK penetration, but poor lung penetration as it is inactivated by pulmonary surfactant<ref>Estes KS and Derendorf K. Comparison of the pharmacokinetic properties of vancomycin, linezolid, tigecyclin, and daptomycin. Eur J Med Res. 2010; 15(12): 533–543.</ref><ref>Silverman JA et al. Inhibition of Daptomycin by Pulmonary Surfactant: In Vitro Modeling and Clinical Impact. J Infect Dis. (2005) 191 (12): 2149-2152.</ref>		*Good soft tissue and MSK penetration, but poor lung penetration as it is inactivated by pulmonary surfactant<ref>Estes KS and Derendorf K. Comparison of the pharmacokinetic properties of vancomycin, linezolid, tigecyclin, and daptomycin. Eur J Med Res. 2010; 15(12): 533–543.</ref><ref>Silverman JA et al. Inhibition of Daptomycin by Pulmonary Surfactant: In Vitro Modeling and Clinical Impact. J Infect Dis. (2005) 191 (12): 2149-2152.</ref>
	**Add MRSA antibiotic with ~~good~~ lung penetration such as [[~~vancomycin~~]] or [[~~clindamycin~~]] ~~if suspicious~~		**Daptomycin is typically added to treat community enterococcus or [[vancomycin-resistant enterococcus]], but VRE pneumonia requires [[linezolid]]
	**Daptomycin is typically added to treat community enterococcus or vancomycin-~~resistant enterococcus~~		**Add MRSA antibiotic with adequate lung penetration such as [[linezolid]] at standard dosing or [[vancomycin]] dosing aimed at higher serum concentrations<ref>Stein GE and Wells EM. The importance of tissue penetration in achieving successful antimicrobial treatment of nosocomial pneumonia and complicated skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus: vancomycin and linezolid. Curr Med Res Opin. 2010 Mar;26(3):571-88.</ref>

	==Adult Dosing==		==Adult Dosing==

Kxl328 at 21:57, 26 August 2016

2016-08-26T21:57:35Z

← Older revision		Revision as of 21:57, 26 August 2016
Line 3:		Line 3:
	*Dosage Forms: IV		*Dosage Forms: IV
	*Common Trade Names: Cubicin		*Common Trade Names: Cubicin
	*Good soft tissue and MSK penetration, but poor lung penetration as it is inactivated by pulmonary surfactant		*Good soft tissue and MSK penetration, but poor lung penetration as it is inactivated by pulmonary surfactant<ref>Estes KS and Derendorf K. Comparison of the pharmacokinetic properties of vancomycin, linezolid, tigecyclin, and daptomycin. Eur J Med Res. 2010; 15(12): 533–543.</ref><ref>Silverman JA et al. Inhibition of Daptomycin by Pulmonary Surfactant: In Vitro Modeling and Clinical Impact. J Infect Dis. (2005) 191 (12): 2149-2152.</ref>
	**Add MRSA antibiotic with good lung penetration such as [[vancomycin]] or [[clindamycin]] if suspicious		**Add MRSA antibiotic with good lung penetration such as [[vancomycin]] or [[clindamycin]] if suspicious
	**Daptomycin is typically added to treat community enterococcus or vancomycin-resistant enterococcus		**Daptomycin is typically added to treat community enterococcus or vancomycin-resistant enterococcus